Format

Send to

Choose Destination
Oncotarget. 2017 Nov 11;8(63):106151-106152. doi: 10.18632/oncotarget.22382. eCollection 2017 Dec 5.

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments.

Author information

1
Jordi Bruix: Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain.

KEYWORDS:

hepatocellular carcinoma; new drugs; sorafenib; systemic treatment; trial design

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center